Trial · NCT04615624

Furosemide vs. Placebo for Severe Antepartum Hypertension

NCT04615624, Phase 3, Completed, Melanie Maykin, MD; results first posted 2024-04-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Furosemide vs. Placebo for Severe Antepartum Hypertension. Trials, record NCT04615624. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04615624

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Furosemide vs. Placebo for Severe Antepartum Hypertension
NCT number: NCT04615624
Status: Completed
Phases: Phase 3
Enrollment: 65 participants, actual
Lead sponsor: Melanie Maykin, MD
Conditions: Pre-Eclampsia, Hypertension in Pregnancy, Pregnancy Complications, Hypertension, Pregnancy-Induced
Interventions: Furosemide, Placebo
First posted: 2020-11-04
Last updated: 2024-04-18
Results first posted: 2024-04-18

Source ClinicalTrials.gov

Registered outcomes21

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Mean Systolic Blood Pressure During Hour After Study Drug	0 minutes to 60 minutes post-dose	Mean systolic blood pressure during hour after study drug administration.
Secondary	Mean Diastolic Blood Pressure During Hour After Study Drug	0 minutes to 60 minutes post-dose	Mean diastolic blood pressure during the 1-hour period after drug administration.
Secondary	Change From Qualifying Systolic Blood Pressure	0 minutes to 1 hour post-dose	Change from qualifying systolic blood pressure (qualifying SBP-mean SBP during hour after intervention) where qualifying systolic blood pressure refers to a severe range SBP (\>=160 millimeters of mercury (mmHg)) for at least 15 minutes.
Secondary	Change From Qualifying Diastolic Blood Pressure	0 minutes to 1 hour post-dose	Change from qualifying diastolic blood pressure (qualifying DBP-mean DBP during hour after intervention) where qualifying diastolic blood pressure refers to a severe range DBP (\>=110 millimeters of mercury (mmHg)) for at least 15 minutes.
Secondary	Pulse Pressure at 2 Hours After Study Drug.	2 hours post-dose	Pulse pressure at 2 hours after study drug.
Secondary	Systolic Blood Pressure at 2 Hours After Study Drug	2 hours post-dose	Systolic blood pressure at 2 hours after study drug
Secondary	Diastolic Blood Pressure at 2 Hours After Study Drug	2 hours post-dose	Diastolic blood pressure at 2 hours after study drug
Other	Gestational Age at Delivery	at the time of birth	Gestational age in weeks and days at the time of birth
Other	Time From Admission to Delivery	at the time of delivery	Time in days and hours from admission to birth
Other	Time From Treatment to Delivery	at the time of delivery	Time in days and hours from treatment to birth

1 to 10 of 21Source ClinicalTrials.gov

See all 21 registered outcomes

Outcomes21

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Mean Systolic Blood Pressure During Hour After Study Drug	0 minutes to 60 minutes post-dose		mmHg	MEAN
SECONDARY	Mean Diastolic Blood Pressure During Hour After Study Drug	0 minutes to 60 minutes post-dose		mmHg	MEAN
SECONDARY	Change From Qualifying Systolic Blood Pressure	0 minutes to 1 hour post-dose		mmHg	MEAN
SECONDARY	Change From Qualifying Diastolic Blood Pressure	0 minutes to 1 hour post-dose		mmHg	MEAN
SECONDARY	Pulse Pressure at 2 Hours After Study Drug.	2 hours post-dose	Not every participant had their blood pressure and thus pulse pressure checked at 2 hours which is a limitation of the study.	mmHg	MEAN
SECONDARY	Systolic Blood Pressure at 2 Hours After Study Drug	2 hours post-dose	Not every participant had their blood pressure checked at 2 hours which is a limitation of the study.	mmHg	MEAN
SECONDARY	Diastolic Blood Pressure at 2 Hours After Study Drug	2 hours post-dose	Not every participant had their blood pressure checked at 2 hours which is a limitation of the study.	mmHg	MEAN
OTHER_PRE_SPECIFIED	Gestational Age at Delivery	at the time of birth		weeks	MEAN
OTHER_PRE_SPECIFIED	Time From Admission to Delivery	at the time of delivery		days	MEDIAN
OTHER_PRE_SPECIFIED	Time From Treatment to Delivery	at the time of delivery		days	MEDIAN

1 to 10 of 21Source ClinicalTrials.gov

See all 21 outcomes

Results by group46

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Mean Systolic Blood Pressure During Hour After Study Drug	Furosemide	147	Standard Deviation 14.8	mmHg
Mean Systolic Blood Pressure During Hour After Study Drug	Placebo	152	Standard Deviation 13.8	mmHg
Mean Diastolic Blood Pressure During Hour After Study Drug	Furosemide	88	Standard Deviation 10.8	mmHg
Mean Diastolic Blood Pressure During Hour After Study Drug	Placebo	87	Standard Deviation 9.3	mmHg
Change From Qualifying Systolic Blood Pressure	Furosemide	-26	Standard Deviation 13.9	mmHg
Change From Qualifying Systolic Blood Pressure	Placebo	-24	Standard Deviation 15.5	mmHg
Change From Qualifying Diastolic Blood Pressure	Furosemide	-12	Standard Deviation 7.6	mmHg
Change From Qualifying Diastolic Blood Pressure	Placebo	-11	Standard Deviation 8.9	mmHg
Pulse Pressure at 2 Hours After Study Drug.	Furosemide	55	Standard Deviation 12.5	mmHg
Pulse Pressure at 2 Hours After Study Drug.	Placebo	67	Standard Deviation 15.1	mmHg

1 to 10 of 46Source ClinicalTrials.gov

See all 46 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Furosemide	33
Overall Study	STARTED	Placebo	32
Overall Study	COMPLETED	Furosemide	33
Overall Study	COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	Furosemide	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals6

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Furosemide	33
Total, all-cause mortality	Placebo	32
Total, other adverse events	Furosemide	33
Total, other adverse events	Placebo	32
Total, serious adverse events	Furosemide	33
Total, serious adverse events	Placebo	32

Source ClinicalTrials.gov

Papers9

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
2234714	BACKGROUND	PubMed
15625138	BACKGROUND	PubMed
20482241	BACKGROUND	PubMed
22179091	BACKGROUND	PubMed
23900968	BACKGROUND	PubMed
28099709	BACKGROUND	PubMed
28333820	BACKGROUND	PubMed
30575675	BACKGROUND	PubMed
38485054	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons6

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Furosemide vs Placebo: Discharged Without Delivery	Trial comparisons
Furosemide vs Placebo: Number of Participants Who Required Additional Antihypertensive Agents in an Hour After Allocation	Trial comparisons
Furosemide vs Placebo: Eclampsia	Trial comparisons
Furosemide vs Placebo: deaths from any cause	Trial comparisons
Furosemide vs Placebo: Induction of Labor	Trial comparisons
Furosemide vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04615624

GET https://conductscience.org/api/trials/v1/NCT04615624/registered?page=2

API reference For AI assistants